The search for an HIV cure: tackling latent infection

Summary Strategies to eliminate infectious HIV that persists despite present treatments and with the potential to cure HIV infection are of great interest. One patient seems to have been cured of HIV infection after receiving a bone marrow transplant with cells resistant to the virus, although this...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2013-07, Vol.13 (7), p.614-621
Main Authors: Kent, Stephen J, Prof, Reece, Jeanette C, MPH, Petravic, Janka, PhD, Martyushev, Alexey, BSc, Kramski, Marit, PhD, De Rose, Robert, PhD, Cooper, David A, Prof, Kelleher, Anthony D, Prof, Emery, Sean, Prof, Cameron, Paul U, PhD, Lewin, Sharon R, Prof, Davenport, Miles P, Prof
Format: Article
Language:English
Subjects:
Antiretroviral agents
Biological and medical sciences
Bone marrow
Bone Marrow Transplantation
Enzyme Inhibitors - administration & dosage
HIV Infections - therapy
HIV Infections - virology
Human immunodeficiency virus
Human viral diseases
Humans
Hydroxamic Acids - administration & dosage
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious Disease
Infectious diseases
Medical sciences
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Virus Activation - drug effects
Virus Latency
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Strategies to eliminate infectious HIV that persists despite present treatments and with the potential to cure HIV infection are of great interest. One patient seems to have been cured of HIV infection after receiving a bone marrow transplant with cells resistant to the virus, although this strategy is not viable for large numbers of infected people. Several clinical trials are underway in which drugs are being used to activate cells that harbour latent HIV. In a recent study, investigators showed that activation of latent HIV infection in patients on antiretroviral therapy could be achieved with a single dose of vorinostat, a licensed anticancer drug that inhibits histone deacetylase. Although far from a cure, such studies provide some guidance towards the logical next steps for research. Clinical studies that use a longer duration of drug dosing, alternative agents, combination approaches, gene therapy, and immune-modulation approaches are all underway.
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(13)70043-4